Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation

Hyunmee Kim, Hyeongsoo Kim, Seong Kyung Cho, Jin Bae Kim, Boyoung Joung, Changsoo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Objectives: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF. Methods: We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation. Results: Number of patients with CHA 2 DS 2 -VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA 2 DS 2 -VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY. Conclusions: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.

Original languageEnglish
Pages (from-to)252-263
Number of pages12
JournalKorean Circulation Journal
Volume49
Issue number3
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Warfarin
Atrial Fibrillation
Cost-Benefit Analysis
Stroke
Quality-Adjusted Life Years
Intracranial Hemorrhages
Costs and Cost Analysis
Rivaroxaban
Incidence
Health Insurance
Embolism
Health Care Costs
Databases
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Hyunmee ; Kim, Hyeongsoo ; Cho, Seong Kyung ; Kim, Jin Bae ; Joung, Boyoung ; Kim, Changsoo. / Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. In: Korean Circulation Journal. 2019 ; Vol. 49, No. 3. pp. 252-263.
@article{91c46a63120a4ee39672318635cdec0d,
title = "Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation",
abstract = "Background and Objectives: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF. Methods: We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation. Results: Number of patients with CHA 2 DS 2 -VASc scores 0, 1 and ≥2 were 56 (0.2{\%}), 1,944 (6.3{\%}) and 28,650 (93.5{\%}), respectively. In patients with CHA 2 DS 2 -VASc scores ≥2, the incidence rate of ischemic stroke was 3.11{\%} and 3.76{\%} in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42{\%} and 0.15{\%}, and those of gastrointestinal bleeding were 0.32{\%} and 0.15{\%} in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY. Conclusions: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.",
author = "Hyunmee Kim and Hyeongsoo Kim and Cho, {Seong Kyung} and Kim, {Jin Bae} and Boyoung Joung and Changsoo Kim",
year = "2019",
month = "1",
day = "1",
doi = "10.4070/kcj.2018.0220",
language = "English",
volume = "49",
pages = "252--263",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "3",

}

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. / Kim, Hyunmee; Kim, Hyeongsoo; Cho, Seong Kyung; Kim, Jin Bae; Joung, Boyoung; Kim, Changsoo.

In: Korean Circulation Journal, Vol. 49, No. 3, 01.01.2019, p. 252-263.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation

AU - Kim, Hyunmee

AU - Kim, Hyeongsoo

AU - Cho, Seong Kyung

AU - Kim, Jin Bae

AU - Joung, Boyoung

AU - Kim, Changsoo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and Objectives: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF. Methods: We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation. Results: Number of patients with CHA 2 DS 2 -VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA 2 DS 2 -VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY. Conclusions: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.

AB - Background and Objectives: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjusted-dose warfarin for the prevention of stroke in patients with nonvalvular AF. Methods: We built a Markov model using the Korean Health Insurance Review & Assessment Service database. The base-case analysis assumed a cohort of patients with prevalent AF who were aged 18 years or older without contraindications to anticoagulation. Results: Number of patients with CHA 2 DS 2 -VASc scores 0, 1 and ≥2 were 56 (0.2%), 1,944 (6.3%) and 28,650 (93.5%), respectively. In patients with CHA 2 DS 2 -VASc scores ≥2, the incidence rate of ischemic stroke was 3.11% and 3.76% in warfarin and rivaroxaban groups, respectively. The incidence rates of ICH were 0.42% and 0.15%, and those of gastrointestinal bleeding were 0.32% and 0.15% in warfarin and rivaroxaban, respectively. Patients with AF treated with rivaroxaban lived an average of 11.8 quality-adjusted life years (QALYs) at a lifetime treatment cost of $20,886. Those receiving warfarin lived an average of 11.4 QALYs and incurred costs of $17,151. Patients with rivaroxaban gained an additional 0.4 QALYs over a lifetime with an additional cost of $3,735, resulting in an incremental cost-effectiveness ratio of $9,707 per QALY. Conclusions: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF.

UR - http://www.scopus.com/inward/record.url?scp=85062281625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062281625&partnerID=8YFLogxK

U2 - 10.4070/kcj.2018.0220

DO - 10.4070/kcj.2018.0220

M3 - Article

VL - 49

SP - 252

EP - 263

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 3

ER -